Unicycive Therapeutics (UNCY): Vivo Opportunity reports 9.99% beneficial ownership stake
Vivo Opportunity Fund Holdings, L.P. and its general partner, Vivo Opportunity, LLC, have reported a 9.99% beneficial ownership stake in Unicycive Therapeutics, Inc. (UNCY). This stake, detailed in an amended Schedule 13G filing, comprises 4,856,259 shares, which includes common stock and shares convertible from …